diagnosed with CML in the chronic phase. Because the patient deliberately opted out of interferon α and tyrosine kinase inhibitor treatment, the main goal was to reduce the leukocyte count to postpone delivery beyond the number of weeks considered severely premature and avoid thromboembolic complications while continuously evaluating the clinical safety of the mother and fetus. Hence therapeutic leukapheresis was initiated, and we report the first application of an apheresis approach for this procedure using the Spectra Optia instrument without sedimentation agents. Leukapheresis was conducted 2 to 4 times per week for 9 weeks.
RESULTS: During treatment the leukocyte count decreased remarkably, and the patient developed lymphopenia together with a paradoxical increase in her blood platelet count. Premature labor was induced at GA 35 weeks, and a healthy boy was delivered. Thereafter, the patient initiated imatinib treatment and was in major molecular and complete cytogenetic remission after 1 year. Despite the remarkable reduction of the leukocyte count, we observed a pronounced increase in expression of BCR-ABL1 transcripts, implying the need for close monitoring of patients with CML during pregnancy.
transcripts were detected, and a t9;22 translocation was subsequently confirmed in the chromosomal analysis. The patient was not described as high risk based on the prognostic scores, 1 and interferon (IFN)-α was recommended as the first-line treatment for the patient during pregnancy. However, the response and risk of side effects of IFN-α were discussed with the patient and her partner, who wished to avoid medical treatment as long as possible to maintain the safety of the fetus as the highest priority. For this reason, a pregnancy-preserving procedure with a course of therapeutic leukapheresis was planned. The overall treatment strategy was primarily to postpone delivery to avoid severe prematurity and reduce the risk of thromboembolic complications. A multidisciplinary team composed of experts in hematology, obstetrics, clinical immunology/blood banking, neonatology, pathology, and cytogenetics/molecular biology, and anesthesiology was established to monitor the course and continuously adjust the treatment, if needed. Therapeutic leukapheresis was initiated at diagnosis, at GA 26 weeks, when the patient's WBC count was 257 × 10 9 cells/L ( Table 1 ). The goal of the leukapheresis procedures was to reduce the WBC count to less than 100 × 10 9 cells/L and the platelet count to less than 600 × 10 9 platelets/L.
1,2
An initial plan of two to three apheresis procedures per week was scheduled. Intravenous access was provided by a two-lumen tunneled central venous catheter placed in the right vena jugularis interna, and anticoagulation was performed using standard procedures with an infusion of anticoagulant citrate dextrose solution A at a ratio of 1:12 and continuous calcium infusion at a rate of 800 mmol/hour to avoid citrate toxicity. Therapeutic leukapheresis is rarely performed, and we were unable to find relevant reports on data regarding the technical performance of the Spectra Optia Apheresis System (Terumo BCT) used in our apheresis center. Furthermore, the company recommended a sedimentation agent to enhance the collection efficiency; however, we deliberately decided against it due to concerns regarding insufficient data on the safety of the available drugs during pregnancy and the increased risk of anaphylactic reactions. Consequently, we used the mononuclear cell (MNC) program for the initial procedure, with which we achieved a decrease in the WBC count (from 257 to 196 × 10 9 cells/L; Table 1 ). However, when repeating the procedure 3 days later, a decrease in the WBC count was not achieved (from 209 to 207 × 10 9 cells/L; Table 1 ). We therefore switched to the white blood cell depletion (WBCD) program and inserted a three-way valve to optimize the collection process. This system allowed continuous sample collection directly from the inlet tube to measure real-time WBC counts and subsequently change the collection preference (CP) to ensure the most efficient leukocyte depletion possible. Also, an additional collection bag was added due to increased output of the WBCD program. Blood samples were drawn from the patient immediately before and after the procedures and analyzed at a routine laboratory. At the beginning of the WBCD program, the CP was automatically set to 75, at which point we collected very few leukocytes (90 × 10 9 cells/L). After learning from a few procedures, we immediately decreased the CP to approximately 55 and collected samples every 20 to 30 minutes at the beginning of the procedure and less frequently by the end of the procedure, ranging from 4 to 13 samples collected during each procedure. When the patient presented a leukocyte count greater than 100 × 10 9 cells/L, the most efficient leukocyte depletion was observed with a CP of 40 to 45. When the patient's leukocyte count was reduced to 100 × 10 9 cells/L or less (at approximately the 16th leukocyte depletion procedure), the most efficient leukocyte depletion was observed at a slightly higher CP of 45 to 50. Furthermore, during each procedure, the optimal CP tended to decrease, and by the end of the procedure, an increased WBC count was observed at a steady CP. Initially, we used isotonic sodium chloride as replacement fluid, but from the sixth leukapheresis onward, we alternated between sodium chloride and plasma to avoid depletion of coagulation factors and other proteins both in general and of specific importance in the present case for the developing fetus. 3 Except for the CP and the processed volume, the standard settings from the manufacturer were used for all procedures including standard packing factor at 4.5 for the WBCD program and 20 for the platelet depletion (PLTD) program, and a collection pump flow rate was automatically calculated based on the patient's WBC/PLT count before apheresis. Twenty leukapheresis procedures were performed over the next 6 weeks, divided into two to four procedures per week; the plan was adjusted continuously. The initial goal of obtaining a WBC count of less than 100 × 10 9 cells/L was achieved after the 16th leukapheresis procedure, at which point the WBC count decreased rapidly to less than 30 × 10 9 cells/L in the following week ( Fig. 1 and Table 1 ). Along with the measurable reduction in the leukocyte count in peripheral blood, the patient's spleen shrank to normal size. The mean rate of WBC depletion was 19.1%, ranging from 1% to 34% (Table 1) , consistent with other similar reports using other apheresis devices. 4 After the 20th leukapheresis session, the WBC count was stabilized at less than 100 × 10 9 cells/L ( Fig. 1 ) and was continuously reduced until it finally stabilized at a leukocyte count of less than 20 × 10 9 cells/L ( Table 1 ). The platelet count initially decreased to numbers within the normal range but increased above the target limit (600 × 10 9 cells/L) as the leukocyte count decreased ( Fig. 1 ). Cell separation was changed to therapeutic thrombapheresis using the PLTD program. However, the product volumes were markedly lower than those obtained during the WBCD program; therefore, despite the presence of a higher platelet count in the products, we collected a lower total number of platelets that consequently led us to alternate between the PLTD and WBCD programs. Because the patient's lymphocyte count was very low at that time, we tried to avoid further use of WBC depletion (Table 1) . For the first 20 procedures, the goal was to reduce the high leukocyte count by leukapheresis, but for the last 7 procedures, the goal was to reduce the high platelet count by thrombapheresis.
Values for leukocyte and platelet counts are shown for each procedure, including the total count measured in the final product, with the exception of the initial two procedures. CP = collection preference; MNC = mononuclear cell; NP = not performed; PLTD = platelet depletion; RBCs = red blood cells; WBCD = white blood cell depletion. * For the purpose of thrombapheresis.
Throughout the apheresis procedures, the patient required red cell transfusions once per week to compensate for anemia caused by pregnancy, untreated CML, and the leukapheresis procedures, and to maintain a hemoglobin level sufficient for fetal development. There was no evidence of hemolysis. Concurrent with the apheresis procedures, the patient was followed closely with a fetal ultrasound every second week to observe abnormal placental echogenicity that could represent microthrombosis induced by CML during the earlier pregnancy (Fig. 2) . Normal fetal development and growth were observed during the pregnancy. Due to an increased risk of thrombosis by CML and pregnancy, and the ischemic impression from the ultrasound scan of the placenta, the patient was treated with low-dose aspirin and low-molecular-weight heparin in prophylactic daily doses throughout the pregnancy and for 2 weeks in the postpartum period. Ultrasound scanning using the Doppler principle at a GA of 27 weeks showed numerous foci that were not distinguishable from ischemic infarcts that appeared to be unaltered until labor was induced (Fig. 2) .
Premature labor was induced at GA 35 weeks due to concerns regarding the patient's persistent lymphopenia. A boy was delivered vaginally without complications and a normal birth weight of 2690 g. The Apgar scores were 8 and 10 after 1 and 5 minutes, respectively. Hospitalization at the neonatal intensive care unit was not required, despite the prematurity. The results of blood tests from the infant were not abnormal, and the child developed normally during his first year.
Overall, the pregnancy was uncomplicated, with no signs of infections, thrombosis, or hemorrhaging. A pathologic examination of the placenta revealed scattered coarse calcifications that probably corresponded to the abnormal echogenicity on ultrasound (Fig. 2 ). An old marginal hematoma and an intervillous thrombus were also observed. No occluding thrombi were present in the fetal circulation, and leukemic infiltrates were not observed (Fig. 3) . The patient began treatment with the tyrosine kinase inhibitor (TKI) imatinib 3 days after delivery and did not breastfeed the infant. The lymphopenia resolved during the first 2 weeks after initiating imatinib. Imatinib was paused for certain periods during the first 3 months due to leukopenia and neutropenia.
At the time of diagnosis, polymerase chain reaction (PCR) detected 36% of BCR-ABL1 expression, corresponding to a typical diagnostic CML sample in the chronic phase. When TKI therapy was begun 10 weeks later, the expression of the BCR-ABL1 fusion transcripts had increased to 44% in the blood, despite the low leukocyte count. After 3, 6, 9, and 13 months, expression of the BCR-ABL1 fusion transcripts had decreased to 0.8%, 0.5%, 0.3%, and 0.009%, respectively (major molecular remission). At diagnosis, a chromosome analysis of stem cells in the peripheral blood showed a variant t(9;22;12)(q34;q11;p13) translocation as the only aberration in 23 of 25 metaphase cells. After 3 months of TKI therapy, the patient had achieved partial cytogenetic remission (3/25 metaphase cells with the t(9;22;12) translocation). At 6 months, the translocation was present in 1 in 26 metaphase cells, and the patient showed complete cytogenetic remission at 12 months.
DISCUSSION
We report a case study of leukapheresis as the only treatment for a patient in the second trimester of pregnancy who presented with a leukocyte count of 250 × 10 9 cells/L and was diagnosed with CML in the chronic phase. At the request of the patient and her spouse, the goal of the treatment was to avoid severe prematurity by postponing delivery, to reduce the risk of thromboembolic events, and to avoid medical CML treatment with IFN-α due to the risk of teratogenic complications. The patient was treated successfully with leukocyte-depleting procedures. The risk of treating CML insufficiently is the potential acceleration of the condition and progression to acute leukemia. No data indicate that progression is more frequent during pregnancy. 1, [5] [6] [7] [8] [9] [10] The progression of CML during pregnancy, however, implies a much more complex situation and a consideration of termination due to the need for combination chemotherapy, the risk to the mother during periods of bone marrow suppression, fetal starvation, and particularly the teratogenic hazard. According to some case reports, pregnancy may be successful in patients treated with TKIs, but these reports may have exhibited positive selection bias. [11] [12] [13] In the present case study, neither the clinical presentation in the chronic phase nor the prognostic factors indicated an imminent risk of disease progression if the patient was not treated with a TKI or IFN-α; thus a balanced decision was achieved together with the parents, who were determined to proceed with the pregnancy. A pregnant woman with a malignant systemic disease should be treated by a multidisciplinary team. 1 The challenge for the hematologist is to manage women with CML who experience an unplanned pregnancy during treatment and the concerns regarding the possible development of accelerated CML to blast crisis upon the discontinuation of cytoreductive treatment during pregnancy or disease activity during a drug holiday in deep molecular remission and pausing the TKI. [5] [6] [7] [8] 14 The management of women diagnosed with CML during pregnancy is another challenge. IFN-α may be an option, but it takes weeks to show an effect in patients with high leukocyte counts, and it may not be tolerated or be ineffective. Leukapheresis is another option when cytoreduction is needed. The challenges for the obstetrician are to ensure the birth of a healthy infant with the lowest risk of complications during pregnancy for the mother and child. Frequent visits to ensure normal fetal blood flow are required, and possible preterm termination of the pregnancy may be required if either the mother or the fetus is at risk. The challenge for the clinical immunologist is to ensure cell separation with optimal leukocyte and thrombocyte reduction through the fewest number of procedures and with the least side effects. In this case study, the team decided to induce labor at a GA of 35 weeks based on the risk to the fetus due to possible ischemia (Fig. 3) , and the risk to the mother because of the untreated leukemia, a potential risk for opportunistic infection due to severe lymphopenia and coagulopathy induced by circumstances and treatment ( Table 1) . The use of leukapheresis as the primary and sole treatment in patients with newly diagnosed CML during pregnancy is rare, and equivalent cases to the one described in the present study must be reported when novel data are observed, especially when introducing the procedure using a new apheresis device (i.e., the Spectra Optia), in contrast to previous reports mainly performed with the Cobe Spectra. However, results may still be difficult to compare from one case to another. 9, 10 In the present case study, leukapheresis procedures were performed more frequently than described in other reports, presumably due to a very high initial leukocyte count and a remarkable increase on the day after each leukapheresis session during the initial course. 9, 10 For the first 20 procedures, the goal was to reduce the high leukocyte count, but for the last 7 procedures, the goal was to reduce the high and increasing platelet count. The continuous adaptation of cell separation by the machine, software, and effect over 10 weeks in this case study may differ from patient to patient, and it may also reflect some biological effect of the apheresis procedure on the CML. In accordance with other case reports, also without the use of a sedimentation agent, we found no reduction in thrombocytes. 9, 10 In contrast, our experience with lymphopenia was not reported by others, and a possible reduction in spleen size was either not found or not reported. 9, 10 Our data revealed an increase in transcript levels measured using PCR over 3 months from diagnosis to disease-specific therapy with TKI, despite the effectiveness of apheresis. PCR data collected during apheresis have not been reported previously, and this case study reflects that the tumor burden was not stabilized or reduced, despite efficient leukocyte depletion (Table 1 and Fig. 1 ). In fact, the transcript level measured using PCR increased by 8% over 10 weeks. The patient was diagnosed with so-called low-risk CML based on prognostic factors. The response status at 6 and 12 months indicated that the patient's molecular remission was not impaired by the 10-week delay in TKI treatment. The variant t(9;22;12)(q34;q11;p13) is not associated with a special clinical phenotype. The increase in the PCR transcript level from 36% to 44% may be expected awaiting a cytoreductive treatment. Also, an increase in platelet count may be observed temporarily during initial treatment with TKI in CML concomitantly with the reduction in WBCs and without other (reactive) causes. It may be speculated that an alteration in the dynamic balance between granulopoiesis and thrombopoiesis induced by the leukapheresis in a similar way contributed to the thrombocytosis. Also, the reduced spleen volume and the following less splenic sequestration may have contributed to the observed thrombocytosis. Repeated imaging was not performed for spleen size, and palpation for spleen size was not possible due to the pregnancy. Nevertheless, the effective results of apheresis and progressive thrombocytosis in this patient may in part represent disease progression because thrombocytosis is characteristic in patients with CML at diagnosis, and the PCR-measured transcript level increased without the administration of a specific therapy. The development of severe lymphopenia with a potential risk of (opportunistic) infection has not been reported previously in patients with CML who are treated with apheresis. The phenomenon illustrates the need for continuous monitoring, including differential counts, and the ability to alter and utilize different apheresis principles and the decisions of the multidisciplinary team.
Umbilical cord blood was deliberately not examined for the presence of the Philadelphia chromosome. One case study previously reported a lack of transmission of CML cells to the fetal circulation. 15 This option represents an ethical issue. CML is not considered inheritable, and a negative result would make the parents feel safe after a turbulent period. However, the test principle is very sensitive, and a false-positive result, resulting from contamination with maternal blood, would be very difficult for the parents to handle while awaiting a follow-up test to exclude potential contamination with maternal blood.
CONCLUSIONS
This case report illustrates the course of CML in the chronic phase in a patient who was diagnosed during the second trimester of pregnancy and treated successfully with cytoreduction solely by apheresis for 9 weeks. Delivery was postponed to the stage after the critical premature age of the fetus at a GA of 35 weeks. During the course of the apheresis procedures, continuous optimization was necessary to obtain satisfactory cytoreduction. Furthermore, based on the results from this case study, we observed an increase in the expression of BCR-ABL1 transcripts of approximately 10% over 10 weeks, despite the significant leukapheresis-induced cytoreduction, indicating progressive disease biology. Subsequently, a repeat PCR analysis of BCR-ABL1 transcripts is recommended in pregnant patients with CML who are undergoing long-term apheresis procedures to monitor the actual disease dynamics and obtain an indirect parameter indicating a need for cytoreductive therapy.
